Amigal will not be filed with FDA until late 2014 or early 2015.
Royalty Pharma is going to court to re-instate its hostile tender offer for Elan following a shareholder vote.
The latest twist in the contentious battle for Elan as it fights a takeover by Royalty Pharma.
Analyst downgrade Myriad following a Supreme Court ruling invalidating patents on human genese.
Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.
A single data slide explains how Vertex will come to dominate cystic fibrosis therapy.
The Court mixed ruling on the patenting of human genes preserves Myriad's cancer-testing business.
Amgen may have a tough time getting FDA approval for trebananib without a survival benefit.
Combinations of various Vertex drugs could benefit 90% of cystic fibrosis patients.
In a bubbly year for the biotech sector, these five stocks stand out over the rest.